Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550277 · ClinicalTrials.gov registry record · Phase 2
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00550277 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 20 participants.
The verdict
NCT00550277, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Inhibition of histone deacetylase (HDAC) provides a novel approach for cancer treatment. LBH589, an oral HDAC inhibitor, has been well tolerated in phase I trials and has shown activity against several types of cancer. In this nonrandomized phase II trial, we are investigating the activity of LBH589 in the treatment of patients with refractory clear cell renal carcinoma.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550277
The ClinicalTrials.gov registry entry for NCT00550277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT00550277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550277 about?
NCT00550277 is a clinical study titled "LBH589 Treatment for Refractory Clear Cell Renal Carcinoma". Inhibition of histone deacetylase (HDAC) provides a novel approach for cancer treatment. LBH589, an oral HDAC inhibitor, has been well tolerated in phase I trials and has shown activity against several types of cancer. In this nonrandomized phase II trial, we are investigating the activity of LBH589...
What is the current status of trial NCT00550277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00550277?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00550277?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.